Accounts Receivable turnover ratio remained unchanged during the first quarter 2026, compared to the previous quarter at 6.32 pointing to a challenging and on top of that deteriorating business climate for the Biotechnology & Pharmaceuticals industry. Average collection period, for Tarsus Pharmaceuticals Inc 's accounts receivable remained unchanged at 58 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 217 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Mar 31 2026 from 656 to 1815.

What is Receivable Turnover Ratio?
What is Tarsus Pharmaceuticals Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

TARS Receivables Turnover Ratio	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Receivable Change	82.7 %	81.25 %	145.3 %	95.32 %	104.56 %
Y / Y Revenue Change	106.87 %	128.39 %	146.68 %	151.54 %	183.68 %
Receivable Turnover Ratio (TTM)	6.32	6.32	5.93	5.83	5.39
TARS's Total Ranking	# 1815	# 656	# 2132	# 1031	#
Accounts Receivable average collection period days	58	58	62	63	68
Seq. Receivable Change	34.55 %	17.18 %	23.4 %	-6.1 %	33.49 %
Seq. Revenue Change	6.85 %	27.78 %	15.62 %	31.05 %	17.96 %

Receivable Turnover Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 22
Healthcare Sector	# 218
Overall Market	# 1815

Receivable Turnover Ratio Statistics
High	Average	Low
59.26	10.35	3.87
(Jun 30 2022)		(Jun 30 2024)

TARS Company Profile • Back to TARS Efficiency Comparisons • Compare TARS Receivables Turnover Ratio to its Competitors

Financial Statements
Tarsus Pharmaceuticals Inc 's Accounts Receivable	$ 117 Millions	Visit TARS's Balance sheet
Tarsus Pharmaceuticals Inc 's Sales TTM	$ 535 Millions	Visit TARS's Income Statement
Sources of TARS's Revenues		Visit TARS's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
TARS's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
TARS's Growth Rates	TARS's Roa	TARS's Inventory Turnover Ratio	TARS's Dividend Comparisons
TARS's Profitability Ratios	TARS's Roi	TARS's Asset Turnover Ratio	TARS's Dividend Growth
TARS's Valuation Ratios	TARS's Roe	TARS's Financial Strength Ratios	TARS's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Mar 31 2026	Receivable at quarter ending Mar 31 2026
Lftd Partners Inc	12.55	$ 36.955 Millions	$ 2.945 Millions
Clene Inc	12.47	$ 0.134 Millions	$ 0.011 Millions
Skinhealth Systems Inc	12.27	$ 295.223 Millions	$ 24.052 Millions
Cytokinetics Incorporated	12.16	$ 105.815 Millions	$ 8.702 Millions
Precision Biosciences Inc	11.94	$ 45.073 Millions	$ 3.776 Millions
Teladoc Health Inc	11.94	$ 2,514.453 Millions	$ 210.660 Millions
Option Care Health Inc	11.65	$ 5,666.577 Millions	$ 486.439 Millions
Ensysce Biosciences Inc	11.55	$ 4.708 Millions	$ 0.407 Millions
Crinetics Pharmaceuticals Inc	11.52	$ 18.069 Millions	$ 1.569 Millions
Icu Medical Inc	11.46	$ 2,156.379 Millions	$ 188.157 Millions
Nrc Health	11.42	$ 138.642 Millions	$ 12.138 Millions
Nuvation Bio Inc	11.41	$ 142.121 Millions	$ 12.454 Millions
Integrated Biopharma Inc	11.34	$ 47.241 Millions	$ 4.165 Millions
National Healthcare Corp	11.07	$ 1,525.905 Millions	$ 137.813 Millions
Vireo Growth Inc.	11.01	$ 350.469 Millions	$ 31.834 Millions
Bioaffinity Technologies Inc	10.79	$ 5.660 Millions	$ 0.525 Millions
Vivos Therapeutics Inc	10.73	$ 19.092 Millions	$ 1.779 Millions
Veracyte Inc	10.68	$ 516.183 Millions	$ 48.353 Millions
Immucell Corporation	10.51	$ 29.035 Millions	$ 2.762 Millions
Kestra Medical Technologies Ltd	10.51	$ 93.819 Millions	$ 8.925 Millions
Lifeloc Technologies Inc	10.41	$ 9.044 Millions	$ 0.869 Millions
Monte Rosa Therapeutics Inc	10.39	$ 42.953 Millions	$ 4.136 Millions
International Stem Cell Corporation	10.23	$ 9.286 Millions	$ 0.908 Millions
Pavmed Inc	10.19	$ 0.107 Millions	$ 0.011 Millions
Viemed Healthcare Inc	10.16	$ 286.565 Millions	$ 28.217 Millions
Addus Homecare Corp	10.14	$ 1,447.070 Millions	$ 142.667 Millions
Utah Medical Products Inc	10.13	$ 36.745 Millions	$ 3.629 Millions
Petvivo Holdings Inc	10.10	$ 0.821 Millions	$ 0.081 Millions
Irhythm Holdings Inc	10.00	$ 787.387 Millions	$ 78.720 Millions
C4 Therapeutics Inc	9.97	$ 34.861 Millions	$ 3.496 Millions

Date modified: 2026-08-29T17:42:36+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.